Publication Author: Sullivan_Sean

• The impact of an ambulatory CPOE system on medication errors.

  Devine EB, Wilson-Norton JL, Lawless NM, Hansen RN, Haney KK, Fisk AW, Sullivan SD. The impact of an ambulatory CPOE system on medication errors. AMIA Annu Symp Proc. 2008 Nov 6:928.

  rakerr2

  November 1, 2008

• A new perspective on concepts of asthma severity and control.

  Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD,

  rakerr2

  September 1, 2008

• Key principles for the improved conduct of health technology assessments for resource allocation decisions.

  Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discu

  rakerr2

  July 1, 2008

• An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.

  Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008 Jun;63(6):670-84. doi: 10.1111/j.1398-9995.2008.01723.x. Review.

  rakerr2

  June 1, 2008

• Medicaid prior authorization and controlled-release oxycodone.

  Morden NE, Zerzan JT, Rue TC, Heagerty PJ, Roughead EE, Soumerai SB, Ross-Degnan D, Sullivan SD. Medicaid prior authorization and controlled-release oxycodone. Med Care. 2008 Jun;46(6):573-80. doi: 10.1097/MLR.0b013e31816493fb.

  rakerr2

  June 1, 2008

• A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach.

  Ramsey SD, Blough DK, Sullivan SD. A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach. Med Care. 2008 May;46(5):542-8. doi: 10.1097/MLR.0b013e318160b479.

  rakerr2

  May 1, 2008

• Cost-effectiveness of lung volume reduction surgery.

  Ramsey SD, Sullivan SD, Kaplan RM. Cost-effectiveness of lung volume reduction surgery. Proc Am Thorac Soc. 2008 May 1;5(4):406-11. doi: 10.1513/pats.200707-095ET.

  rakerr2

  May 1, 2008

• The promise of specialty pharmaceuticals: are they worth the price?

  Sullivan SD. The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm. 2008 May;14(4 Suppl):S3-6.

  rakerr2

  May 1, 2008

• An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.

  Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics. 2008;26(4):329-39.

  rakerr2

  April 1, 2008

• HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.

  Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health. 2008 Mar-Apr;11(2):131-8. doi: 10.1111/j.1524-4733.2007.00221.x.

  rakerr2

  March 1, 2008